



Section 18: Infection. Includes checkboxes for abscess, cellulitis, meningitis, pneumonia, etc.

Section 19: Chronic Conditions. Includes checkboxes for cystic fibrosis, diabetes, heart disease, liver disease, etc.

Section 20: Substance Use. Includes checkboxes for smoking, alcohol abuse, and other substances like marijuana and opioids.

Section 21: Central Line. Includes checkboxes for central line placement, date of discharge, and facility ID.

Section 22: Weight. Includes fields for weight in lbs, oz, kg and height in ft, in, cm.

Section 23: Patient History. Includes checkboxes for international travel, hospitalization while visiting, and other patient history details.



IFB971 @H F9G' CB@M &2" F97CF8 'H<9' 7C@CBM7 CI BH.

IFB971 @H F9G'CB@M & . G= BG5B8 'GMADHCAG'5GGC7-5H98 'K H<'1 F-B9 71 @H F9"

Please indicate if any of the following symptoms were reported during the 5 day time period including the 2 calendar days before through the 2 calendar days after the DISC.

- BcbY □ I_b_bck b □ Costovertebral angle pain or tenderness □ Frequency □ Dysuria □ Suprapubic tenderness □ Fever [temperature ≥ 100.4 °F (38 °C)] □ Urgency □ Apnea □ Bradycardia □ Lethargy □ Vomiting

&4U" =G5BH A7FC6-5 @I G9'fW'CF CF5 @-B'H<9' '\$85MG'69: CF9'H<9'8-G7'8C7I A9BH983' □ Yes □ No □ Unknown

&4V" = 'M9GZ7 <9? '5 @@5BH A7FC6-5 @G1 G98 '-B'H<9' '\$85MG'69: CF9'H<9'8-G7 . f7\ YW'U''h UhUdd'nl'..... □ Unknown

- Amikacin □ Cefazolin □ Cefdinir □ Cefepime □ Cefiderocol □ Cefixime □ Cefotaxime □ Cefoxitin □ Cefpodoxime □ Ceftaroline □ Ceftriaxone □ Cefuroxime □ Cephalixin □ Ciprofloxacin □ Clarithromycin □ Clindamycin □ Dalbavancin □ Daptomycin □ Delafloxacin □ Doripenem □ Doxycycline □ Ertapenem □ Eravacycline □ Fidaxomicin □ Fosfomycin □ Gentamicin □ Imipenem/cilastatin □ Levofloxacin □ Linezolid □ Meropenem □ Meropenem/vaborbactam □ Metronidazole □ Moxifloxacin □ Nitrofurantoin □ Omadacycline □ Oritavancin □ Penicillin □ Piperacillin/tazobactam □ Polymyxin B □ Polymyxin E (colistin) □ Rifaximin □ Tedizolid □ Telavancin □ Tigecycline □ Tobramycin □ Trimethoprim □ Trimethoprim/sulfamethoxazole □ Vancomycin □ IV □ PO □ Other (specify): □ Other (specify):

REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.

&5a" DID 'H<9' D5H9BH HAVE A POSITIVE TEST(S) FOR 'G5FGI7 cJ1& fA C@71 @F'5G65 MZG9FC@; MCF' CH<9F'7CB: -F A5HCFMH9GH'CB'CF' 69: CF9'H<9'8-G7 3'

&5b. IF YES, COMPLETE TABLE BELOW:

- Yes □ No □ Unknown

Table with 3 columns: Test description, Specimen collection date, Test type. Rows for 'FIRST positive test for SARS-CoV-2' and 'MOST RECENT positive test for SARS-CoV-2'.

&5W7 CJ-8 IB9H75 G9' -8.

&5X" BB8 GG-8 g'fD@5 G9' DFCJ-89'5H'@5GH'CB9'C: 'H<9' : C@C'K-B; 'K <9B'5DD@7 56 @L

@W'cUgY-8. @W'rYw'fX'-8. GHU'VUgY'X'YbHjZ'Yf. @[U'w'vUgY'X'YbHjZ'Yf. CDC 2019-nCoV ID: _____

&6U" K 5 G'H<9' -B7 -8 9BH GD97 -A9B' DC @MA -7 FC6-5 @

&6c" IF TESTED, WHAT TESTING METHOD WAS USED3 (Check all that apply):

&6d" IF TESTED, WHAT WAS THE RESULT:

- Yes □ No □ Unknown

26b. WAS THE INCIDENT SPECIMEN TESTED FOR ESBL PRODUCTION OR OTHER BETA-LACTAMASE GENES?

- Yes □ No □ Laboratory not testing □ Unknown

- Broth Microdilution (AT1 detection) □ ESBL well □ Expert rule (AT1 flag) □ Unknown □ Broth Microdilution (Manual) □ Disk Diffusion □ E-test □ Molecular test (specify): □ Gene variant (specify): □ Other non-molecular test (specify):

- Positive □ Negative □ Indeterminate □ Unknown (repeated for each test type)



2+ "GI G7 9DH6 =GHMF9GI @HG.

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available

8 UH Gci fVW	Medical Record		Microscan		Vitek		Phoenix		Sensititre		Kirby-Bauer		E-test	
5 bhjVchjW	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	MIC	Interp	Zone Diam	Interp	MIC	Interp
5 a j_UWj b														
5 a cl jW j b#`Uj i`UbUH Y														
5 a d jW j b														
5 a d jW j b#Gi`VUWUa														
5 n f Y c b U a														
7 YZ jnc`j b														
7 9: 9 D=A 9														
7 YZ XYfc Vc`														
7 9: CH5 L=A 9														
7 YZ: l j j b														
7 9: H5 N8=A 9														
7 YZ U j X j a Y# j j VUWUa														
7 YZ c`cnUb Y# Hunc VUWUa														
7 9: HF-5 LCB9														
7 Yd U c H j b														
7 j d f c Z c l U j b														
7 C @GH-B														
8 CF=D9 B9 A														
8 cl n W W j b Y														
9 f U j U W W j b Y														
9 F H5 D9 B9 A														
: c g Z: a n W j b														
; Y b H U a j W j b														
=A=D9 B9 A														
=a j d Y b Y a ! f Y Y V U W U a														
@ j c Z c l U j b														
A 9 F C D9 B9 A														
A Y f c d Y b Y a ! j U V c f V U W U a														
A j b c W W j b Y														
B j f c Z f U b c j b														
Ca U X U W W j b Y														
D j d Y f U W j b # H u n c V U W U a														
D`Unca j W j b														
DC @MA ML-B`6														
F j Z l a d j b														
H Y f U W W j b Y														
H; 97 M7 @B9														
H c V f U a n W j b														
Trimethoprim-sulfamethoxazole														

28a. WAS CASE FIRST IDENTIFIED THROUGH AUDIT? Yes No

28b. CRF STATUS: Complete Pending Chart unavailable after 3 requests

28c. SO INITIALS: _____

28d. DATE OF ABSTRACTION: _____

28e. COMMENTS: _____